Renal Status
- Clinicians should assess CrCl in all patients with HCV. (A1)
- Clinicians new to HCV treatment should consult a liver disease specialist when treating patients with severe renal impairment (CrCl <30 mL/min). (A3)
HAV and HBV Immunity Status
- Clinicians should obtain HAV antibody (IgG or total) testing and administer the full HAV vaccine series in patients who are not immune to HAV. (A3)
- Clinicians should obtain HBsAg, anti-HBs, and anti-HBc test results (total) and should recommend administration of the HBV vaccine series (at 0, 1, and 6 months) for HBV-susceptible patients (negative for all serologies). (A3)
- In patients with positive HBsAg test results, clinicians should perform HBV DNA testing to assess for active HBV infection. (A1)
- If HBV DNA is detectable, clinicians new to HCV treatment should consult a clinician experienced in managing both HBV and HCV. (A1)
